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ABSTRACT
Background: Elderly patients, especially those with Alzheimer’s disease, may
be prescribed memantine and an antiepileptic drug concurrently.
Objective: The aim of this study was to compare the interaction of memantine 
with phenobarbital (an enzyme inducer) and chloramphenicol (an enzyme inhibitor)
on plasma concentrations of carbamazepine (CBZ), CBZ-10,11-epoxide (CBZE), and
phenytoin in an experimental model.
Methods: Eight groups of rats (200–230 g) were treated for 14 days each. In 
groups 1 and 2, phenobarbital 50 mg/kg was administered daily as an enzyme inducer 
60 minutes before CBZ 50 mg/kg or phenytoin 30 mg/kg administration, respec-
tively. In groups 3 and 4, chloramphenicol 300 mg/kg was administered daily as an 
enzyme inhibitor 60 minutes before CBZ or phenytoin administration, respectively.
In groups 5 and 6, memantine 20 mg/kg was administered daily 60 minutes before
CBZ or phenytoin, respectively. In group 7, CBZ alone was administered daily; in
group 8, phenytoin alone was administered daily. Two hours after the last intragastric
gavage, animals were anesthetized with ether and 2 mL of blood was drawn from the
heart into a syringe containing EDTA. A validated method developed in this study
was used for simultaneous determination of CBZ, CBZE, and phenytoin concentra-
tions in rat plasma.
Results: The study comprised 8 groups of 9 male adult Wistar rats each. Com-
pared with groups 7 and 8, concurrent use of CBZ or phenytoin with phenobarbital
(groups 1 and 2) was associated with significantly lower mean (SEM) plasma con-
centrations of CBZ (3.45 [0.16] vs 2.20 [0.21] μg/mL; P < 0.001) and phenytoin
(3.68 [0.09] vs 1.63 [0.15] μg/mL; P < 0.001) and a significantly higher plasma 
CBZE concentration (9.85 [0.29] vs 11.18 [0.29] μg/mL; P < 0.05). Concurrent use
of CBZ or phenytoin with chloramphenicol (groups 3 and 4) was associated with 
significantly higher plasma concentrations of CBZ (4.81 [0.17] μg/mL; P < 0.001)
and phenytoin (6.24 [0.22] μg/mL; P < 0.001) and a significantly lower plasma CBZE
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concentration (3.88 [0.25] μg/mL; P < 0.001). Concurrent use of CBZ or phenytoin
with memantine (groups 5 and 6) was not associated with a significant change in the 
plasma concentration of CBZ, CBZE, or phenytoin.
Conclusion: Memantine was not associated with a significant change in the
plasma concentration of CBZ, CBZE, or phenytoin in this experimental model.
(Curr Ther Res Clin Exp. 2009;70:359–365) © 2009 Excerpta Medica Inc.
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INTRODUCTION
Memantine, a dimethylated derivative of amantadine, is an antagonist of N-methyl-
d-aspartate receptors that reduces glutamate activity. Overexcitation of glutamate
receptors may play a role in both Alzheimer’s disease and epilepsy.1 Memantine and
antiepileptic drugs may be used concurrently. Carbamazepine (CBZ) is a first-line 
treatment for generalized tonic-clonic and partial seizures.1 This drug is metabolized
by the cytochrome (CYP) P450 enzyme system to different metabolites. One of the
most clinically important metabolites is CBZ-10,11-epoxide (CBZE), which is phar-
macologically active.2–4 Phenytoin is also an antiepileptic agent, indicated for psycho-
motor and generalized seizure, that is a substrate to the CYP450 enzyme system.5
Phenobarbital is a potent inducer of isoenzymes of CYP450 (eg, 1A2, 2C9, 2D6, 
3A4), while chloramphenicol is an inhibitor of CYP isoforms (eg, 2C9, 2C19, 3A4).6,7
CYP450s play a key role in the oxidation of numerous endogenous and exogenous 
compounds. Phenobarbital and chloramphenicol decrease and increase, respectively,
the plasma concentration of several drugs (eg, CBZ and phenytoin).7 In this study we
used these drugs as an inducer and an inhibitor, respectively, of the CYP450 system.
An in vitro investigation found that despite mild inhibition of CYP2D6 catalytic 
activity, memantine did not interact with other CYP-metabolized drugs at the clini-
cally relevant concentrations achieved during therapy.8
The aim of this study was to compare the interaction between memantine and 
phenobarbital (an enzyme inducer) and chloramphenicol (an enzyme inhibitor) on
plasma concentrations of CBZ, CBZE, and phenytoin in an experimental model. 
MATERIALS AND METHODS
Experimental Design
Male adult Wistar rats weighing 200 to 230 g were used in this study. All animals
were given food and water ad libitum. Animals were housed 4 per cage and main-
tained at 22°C (±2°C) with a controlled 12-hour light-dark cycle. There were ≥7 days
between the arrival of the animals at the study site and the onset of the experiments. 
The animals were handled in accordance with the criteria and recommendations of the 
ethics committee on animal experiments of the School of Medicine, Tehran University 
of Medical Sciences, Tehran, Iran. 
Animals were randomly divided into 8 groups, all of which were treated daily for 
14 days with CBZ 50 mg/kg or phenytoin 30 mg/kg. Animals in group 1 were pre-
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treated with phenobarbital 50 mg/kg daily 60 minutes before CBZ administration.9
Animals in group 2 were pretreated with phenobarbital 50 mg/kg daily 60 minutes 
before phenytoin administration. Animals in group 3 were pretreated with chloram-
phenicol 300 mg/kg daily 60 minutes before CBZ administration.10 Animals in
group 4 were pretreated with chloramphenicol 300 mg/kg daily 60 minutes be-
fore phenytoin administration. Animals in group 5 were pretreated with meman-
tine 20 mg/kg daily 60 minutes before CBZ administration.11 Animals in group 6 
were pretreated with memantine 20 mg/kg daily 60 minutes before phenytoin ad-
ministration. In group 7 (CBZ control), only CBZ was administered,12,13 and in group 8 
(phenytoin control), only phenytoin was administered.14 All drugs were administered
via intragastric gavage. 
Chemicals
The following chemicals were used in the study: CBZ (Sobhan Pharmaceutical 
Co., Rasht, Iran), phenytoin (Amin Pharmaceutical Co., Isfahan, Iran), chloram-
phenicol (Hakim Pharmaceutical Co., Tehran, Iran), and phenobarbital (Darou-
Pakhsh Pharmaceutical Co., Tehran, Iran). CBZE and memantine were purchased
from Sigma (St. Louis, Missouri); methanol, 2-propanol, and acetonitrile were pur-
chased from Caledon Laboratories Ltd. (Georgetown, Canada); and dipotassium
hydrogen phosphate anhydrous and orthophosphoric acids were purchased from
Merck KGaA (Darmstadt, Germany).
Blood Collection for Preparation of Plasma
Two hours after the last intragastric gavage on day 14, animals were anesthetized
with ether and 2 mL of blood was drawn from the heart into a syringe containing
EDTA with a final EDTA concentration of 1 g/L, transferred to plastic tubes, and 
centrifuged at 2325g for 15 minutes. The aliquots were kept frozen at –70°C until 
analysis.
HPLC
A validated method, developed in this study, was used for simultaneous determina-
tion of CBZ, CBZE, and phenytoin concentrations in rat plasma. The instruments
used included a WellChrom Maxi-Star K-1000 pressure pump, a WellChrom K-2500 
spectrophotometer, a K-5003 4-channel degasser, and a data processor using 
EuroChrom 2000 software, all from Knauer (Berlin, Germany). Separation was per-
formed on a C18 analytical column (Nova-Pak, Waters Corp., Milford, Ireland; 250 × 
4.6 mm, 4 μm inner diameter). The column temperature was set at 25°C using a
space column heater (Grace Vydac Inc., Worms, Germany). The mobile phase con-
sisted of phosphate buffer-acetonitrile-2-propanol (63:22:15, v/v/v) at a pH adjusted 
to 6.0 using orthophosphoric acid. The mobile phase was always freshly prepared and
was filtered using a vacuum filter system equipped with 0.45-μm membrane filter
(Millipore Corp., Billerica, Massachusetts) and degassed for 15 minutes. The phos-
phate buffer was prepared by dissolving 1.78 g of potassium dihydrogen phosphate in 
200 mL of doubly distilled water. Chromatography was performed at 25°C by pump-
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ing the mobile phase at a flow rate of 1 mL/min. The column effluent was monitored
at 220 nm. The obtained limits of quantitation were 0.330, 0.350, and 0.322 mg/L 
for CBZ, CBZE, and phenytoin, respectively.
Sample Preparation
Each of the specimens was prepared for analysis according to the following procedure.
To a 200-μL plasma sample, 200 μL of acetonitrile was added and mixed well for 2 min-
utes. Then 200 μL of mobile phase was added and the resulting mixture was again 
mixed well for 2 minutes. The mixture was then centrifuged at 7826g for 5 minutes,
and the supernatant was injected into the system using a 20-μL injection loop. 
Statistical Analysis
Values were reported as mean (SEM). One-way ANOVA and Tukey post hoc tests 
were used to determine mean differences. P < 0.05 was considered statistically signifi-
cant. Calculations were performed using SPSS version 11 (SPSS Inc., Chicago, Illinois).
RESULTS
The study comprised 8 groups of 9 male adult Wistar rats each. All animals survived 
up to the end of study. 
The animals in groups 1 and 2 were pretreated with phenobarbital 60 minutes 
before CBZ or phenytoin administration. Mean (SEM) plasma concentrations of CBZ
and CBZE in group 1 were 2.20 (0.21) and 11.18 (0.29) μg/mL, respectively. In 
group 2, the plasma phenytoin concentration was 1.63 (0.15) μg/mL. Compared with
the control groups (7 and 8), concurrent use of phenobarbital was associated with
significantly lower plasma CBZ (group 7, 3.45 [0.16] μg/mL; P < 0.001) and pheny-
toin (group 8, 3.68 [0.09] μg/mL; P < 0.001) concentrations and a significantly
higher plasma CBZE concentration (group 7, 9.85 [0.29] μg/mL; P < 0.05) (Table).
The animals in groups 3 and 4 were pretreated with chloramphenicol 60 minutes 
before CBZ or phenytoin administration. Mean (SEM) plasma concentrations of CBZ
and CBZE in group 3 were 4.81 (0.17) and 3.88 (0.25) μg/mL, respectively. In
group 4, the plasma phenytoin concentration was 6.24 (0.22) μg/mL. Concurrent use
of chloramphenicol was associated with significantly higher plasma CBZ (P < 0.001)
and phenytoin (P < 0.001) concentrations and a significantly lower plasma CBZE 
concentration (P < 0.001) compared with the control groups (Table).
The animals in groups 5 and 6 were pretreated with memantine 60 minutes before 
CBZ or phenytoin administration. In group 5, mean (SEM) plasma concentrations of 
CBZ and CBZE were 3.68 (0.15) and 9.27 (0.27) μg/mL, respectively. In group 6, 
plasma phenytoin concentration was 3.62 (0.17) μg/mL. Concurrent use of meman-
tine was not associated with a significant change in plasma CBZ, CBZE, or phenytoin 
concentration compared with the control groups (Table). 
DISCUSSION
In this study, we investigated the effect of memantine on the plasma concentrations
of CBZ, CBZE, and phenytoin. A number of drugs, such as phenobarbital and rifam-
3
6
3
A
.R
. K
a
r
a
m
i B
o
n
a
r
y
 e
t
 a
l
.
Table. Plasma concentrations of carbamazepine (CBZ), CBZ-10,11-epoxide (CBZE), and phenytoin (PHE) after 14 days of 
treatment (N = 72). Data are mean (SEM) μg/mL.
Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 Group 7 Group 8
Drug (PB + CBZ) (PB + PHE) (CAP + CBZ) (CAP + PHE) (MMT + CBZ) (MMT + PHE) (CBZ) (PHE)
CBZ 2.20 (0.21)* – 4.81 (0.17)* – 3.68 (0.15) – 3.45 (0.16) –
CBZE 11.18 (0.29)† – 3.88 (0.25)* – 9.27 (0.27) – 9.85 (0.29) –
PHE – 1.63 (0.15)‡ – 6.24 (0.22)‡ – 3.62 (0.17) – 3.68 (0.09)
PB = phenobarbital; CAP = chloramphenicol; MMT = memantine.
*P < 0.001 versus group 7.
†P < 0.05 versus group 7.
‡P < 0.001 versus group 8.
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pin, increase the activity of microsomal oxidase and conjugating reactions when ad-
ministered repeatedly.15 Enzyme induction is an important cause of drug interactions. 
Drugs that cause enzyme induction usually decrease the pharmacologic activity of 
other drugs metabolized by the same enzymes. Enzyme inhibition (particularly of the 
CYP450 system) slows the metabolism and increases the action of other drugs me-
tabolized by the same enzyme. Such effects can be clinically important and are
important considerations in the treatment of patients. Drugs that inhibit drug-
metabolizing enzymes include chloramphenicol, cimetidine, allopurinol, erythromycin, 
ritonavir, and ciprofloxacin.15 Phenobarbital has been found to induce human liver
microsomal enzymes and was associated with a lower plasma concentration of CBZ 
and phenytoin and a higher plasma concentration of CBZE.6 Chloramphenicol inhib-
ited CYP450-mediated metabolism of CBZ and phenytoin,7 resulting in higher
plasma CBZ and phenytoin concentrations and a lower plasma CBZE concentration.
Limitations of this study included the open design and the small number of rats 
used in each group. Also, the plasma concentration of memantine was not assessed.
Therefore, large, controlled studies in humans are needed to confirm these results.
CONCLUSION
Memantine was not associated with a significant change in the plasma concentration 
of CBZ, CBZE, or phenytoin in this experimental model.
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